Paul Kim Sells 662 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGTGet Rating) CFO Paul Kim sold 662 shares of Fulgent Genetics stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $41.39, for a total transaction of $27,400.18. Following the transaction, the chief financial officer now directly owns 149,507 shares in the company, valued at approximately $6,188,094.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Fulgent Genetics Stock Performance

FLGT stock opened at $44.28 on Friday. Fulgent Genetics, Inc. has a one year low of $41.10 and a one year high of $109.55. The company’s fifty day moving average price is $52.96 and its 200-day moving average price is $55.15. The company has a market capitalization of $1.34 billion, a PE ratio of 3.52 and a beta of 1.55.

Fulgent Genetics (NASDAQ:FLGTGet Rating) last released its earnings results on Thursday, August 4th. The company reported $0.59 EPS for the quarter, hitting the consensus estimate of $0.59. Fulgent Genetics had a net margin of 42.41% and a return on equity of 33.04%. The firm had revenue of $125.30 million for the quarter, compared to the consensus estimate of $122.70 million. During the same quarter in the previous year, the firm earned $2.47 earnings per share. The company’s quarterly revenue was down 18.4% compared to the same quarter last year. On average, research analysts predict that Fulgent Genetics, Inc. will post 5.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Credit Suisse Group assumed coverage on shares of Fulgent Genetics in a report on Wednesday, August 24th. They set an “outperform” rating and a $65.00 price target on the stock. Piper Sandler lowered their price target on shares of Fulgent Genetics from $85.00 to $70.00 in a report on Sunday, May 15th. Finally, TheStreet downgraded shares of Fulgent Genetics from a “b-” rating to a “c+” rating in a report on Thursday, July 28th.

Hedge Funds Weigh In On Fulgent Genetics

Several hedge funds have recently modified their holdings of the stock. Total Clarity Wealth Management Inc. purchased a new stake in Fulgent Genetics during the second quarter valued at $29,000. Geneos Wealth Management Inc. raised its stake in Fulgent Genetics by 416.8% during the first quarter. Geneos Wealth Management Inc. now owns 491 shares of the company’s stock valued at $30,000 after purchasing an additional 396 shares in the last quarter. First Quadrant LLC CA purchased a new stake in Fulgent Genetics during the first quarter valued at $43,000. Nisa Investment Advisors LLC purchased a new stake in Fulgent Genetics during the first quarter valued at $44,000. Finally, Rise Advisors LLC purchased a new stake in Fulgent Genetics during the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 43.22% of the company’s stock.

About Fulgent Genetics

(Get Rating)

Fulgent Genetics, Inc, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests.

Featured Stories

Insider Buying and Selling by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with's FREE daily email newsletter.